Olumiant long-term safety profile established up to 9.3 years in integrated analysis of more than 3,700 patients with rheumatoid arthritis.
Eli Lilly and Company and Incyte will present these results, along with real-world safety results from 3,445 patients with RA in Japan, at ACR Convergence 2021, the American College of Rheumatology's virtual annual meeting taking place November 3-9, 2021. Detailed and additional results from the long-term, integrated safety study for OLumiant were recently published in the Annals of the Rheumatic Diseases.
Olumiant RA Safety Profile Remains Consistent Up to 9.3 Years: A pooled analysis across nine randomized studies and one long-term extension study evaluated the safety of Olumiant 4-mg and Olumiant 2-mg over time in 3,770 patients with RA, who were exposed to treatment for a total of 14,744 patient years of exposure. Participants had a median exposure of 4.6 years and a maximum exposure of 9.3 years. Among those treated with Olumiant, the overall incidence rate of adverse events per 100 patient years of exposure was 22.6, and the incidence rate of serious adverse events was 7.4. Incidence rates remained stable over time across the 14,744 patient years of exposure. The incidence rate of serious infections was 2.58 per 100 patient years of exposure. Adverse events of special interest included venous thromboembolic events (pulmonary embolism, incidence rate=0.26; deep vein thrombosis, incidence rate=0.35; deep vein thrombosis and/or pulmonary embolism, incidence rate=0.49) and major adverse cardiovascular events (incidence rate=0.51) within the range of incidence rates described in epidemiological studies in the general RA population. Incidence rates of safety events of special interest among those treated with OLUMIANT remained stable through exposures up to 9.3 years and were generally similar between the Olumiant 2-mg and 4-mg groups. In a subgroup of patients over 50 years old who had at least one cardiovascular risk factor (current smoker, hypertension, high-density lipoprotein cholesterol <40 mg dl, diabetes, or arteriosclerotic cardiovascular disease), the incidence rate of major adverse cardiovascular events (mace) was 0.77 per 100 patient years of exposure vs. 0.51 in the total study population. in this study, age-adjusted incidence rates for malignancy (incidence rate="0.92)" and mortality (incidence rate="0.6)" for patients treated with olumiant appear similar to the general u.s. population.></40>
Real-World Evidence Study Reinforces Olumiant 4-mg and 2-mg Safety Profile at 24-Weeks: A post-marketing surveillance study of 3,445 patients with RA in Japan evaluated the safety of Olumiant 4-mg and Olumiant 2-mg in clinical practice and no new safety signals were identified. Of the population, 54% were 65 years or older, and 65% started with an initial dose of OLUMIANT 4-mg/day. Three out of four patients in the study (74%) continued treatment for 24 weeks, and the majority of patients maintained a consistent dosage. Overall, 26% of patients (n=887) reported an adverse event and 4% of patients (n=122) reported a serious adverse event, with six deaths, none of which were related to deep vein thrombosis or pulmonary embolisms. Priority survey events included herpes zoster (3%, n=100), liver dysfunction (3%, n=100), serious infection (1.5%, n=51), anemia (1%, n=41), hyperlipidemia (1%, n=40), malignancy (0.3%, n=11), interstitial pneumonia (0.2%, n=8), MACE (0.1%, n=5) and venous thromboembolism (0.1%, n=3).
See-"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database" Peter C Taylor, Tsutomu Takeuchi, Gerd R Burmester, Patrick Durez, Kevin L Winthrop. et al. To view, please visit the journal online (http:// dx. doi. org/ 10. 1136/ annrheumdis- 2021- 221276)
Related news and insights
EQRx, Inc. a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, announced that data from its partner CStone Pharmaceuticals’ two pivotal Phase III studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer (NSCLC), GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) announced that the European Commission has approved Tavneos (avacopan) in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis.
Pfizer Inc. shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), is maintained against the SARS-CoV-2 variant Omicron.